These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

774 related articles for article (PubMed ID: 29290076)

  • 1. Risk of serious infections in biological treatment of patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
    Wang S; He Q; Shuai Z
    Clin Rheumatol; 2018 Feb; 37(2):439-450. PubMed ID: 29290076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
    Callhoff J; Sieper J; Weiß A; Zink A; Listing J
    Ann Rheum Dis; 2015 Jun; 74(6):1241-8. PubMed ID: 24718959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis).
    Kroon FP; van der Burg LR; Ramiro S; Landewé RB; Buchbinder R; Falzon L; van der Heijde D
    Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD010952. PubMed ID: 26186173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumour necrosis factor-α inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation.
    Corbett M; Soares M; Jhuti G; Rice S; Spackman E; Sideris E; Moe-Byrne T; Fox D; Marzo-Ortega H; Kay L; Woolacott N; Palmer S
    Health Technol Assess; 2016 Feb; 20(9):1-334, v-vi. PubMed ID: 26847392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of biological DMARDs: a systematic literature review informing the 2022 update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis.
    Webers C; Ortolan A; Sepriano A; Falzon L; Baraliakos X; Landewé RBM; Ramiro S; van der Heijde D; Nikiphorou E
    Ann Rheum Dis; 2023 Jan; 82(1):130-141. PubMed ID: 36270657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of non-radiographic axial spondyloarthritis and ankylosing spondylitis patients--baseline characteristics, treatment adherence, and development of clinical variables during three years of anti-TNF therapy in clinical practice.
    Wallman JK; Kapetanovic MC; Petersson IF; Geborek P; Kristensen LE
    Arthritis Res Ther; 2015 Dec; 17():378. PubMed ID: 26703005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of infections in psoriatic arthritis or axial spondyloarthritis patients treated with targeted therapies: A meta-analysis of randomized controlled trials.
    Séauve M; Auréal M; Laplane S; Lega JC; Cabrera N; Coury F
    Joint Bone Spine; 2024 May; 91(3):105673. PubMed ID: 38042364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
    van der Heijde D; Dougados M; Landewé R; Sieper J; Maksymowych WP; Rudwaleit M; Van den Bosch F; Braun J; Mease PJ; Kivitz AJ; Walsh J; Davies O; Bauer L; Hoepken B; Peterson L; Deodhar A
    Rheumatology (Oxford); 2017 Sep; 56(9):1498-1509. PubMed ID: 28498975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) from a single rheumatology clinic in New Delhi.
    Malaviya AN; Kalyani A; Rawat R; Gogia SB
    Int J Rheum Dis; 2015 Sep; 18(7):736-41. PubMed ID: 26172961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adalimumab for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis - a five-year update.
    Poddubnyy D; Rudwaleit M
    Expert Opin Biol Ther; 2013 Nov; 13(11):1599-611. PubMed ID: 24074224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Comparative Safety of TNF Inhibitors in Ankylosing Spondylitis-a Meta-Analysis Update of 14 Randomized Controlled Trials.
    Hou LQ; Jiang GX; Chen YF; Yang XM; Meng L; Xue M; Liu XG; Chen XC; Li X
    Clin Rev Allergy Immunol; 2018 Apr; 54(2):234-243. PubMed ID: 28717941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, safety and cost per responder of biologics in the treatment of non-radiographic axial spondyloarthritis.
    Olivieri I; Fanizza C; Gilio M; Ravasio R
    Clin Exp Rheumatol; 2016; 34(5):935-940. PubMed ID: 27385374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ankylosing Spondylitis versus Nonradiographic Axial Spondyloarthritis: Comparison of Tumor Necrosis Factor Inhibitor Effectiveness and Effect of HLA-B27 Status. An Observational Cohort Study from the Nationwide DANBIO Registry.
    Glintborg B; Sørensen IJ; Østergaard M; Dreyer L; Mohamoud AA; Krogh NS; Hendricks O; Andersen LS; Raun JL; Kowalski MR; Danielsen L; Pelck R; Nordin H; Pedersen JK; Kraus DG; Christensen SR; Hansen IM; Esbesen J; Schlemmer A; Loft AG; Al Chaer N; Salomonsen L; Hetland ML
    J Rheumatol; 2017 Jan; 44(1):59-69. PubMed ID: 27909080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can we reduce the dosage of biologics in spondyloarthritis?
    Olivieri I; D'Angelo S; Padula A; Leccese P; Nigro A; Palazzi C
    Autoimmun Rev; 2013 May; 12(7):691-3. PubMed ID: 22940233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of biologics on health-related quality of life in patients with Ankylosing spondylitis: A systematic review and meta-analysis of randomized controlled trials.
    Ho A; Younis I; Le QA
    Semin Arthritis Rheum; 2022 Jun; 54():151996. PubMed ID: 35339841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Similar biologic drug response regardless of radiographic status in axial spondyloarthritis: data from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis registry.
    Michelena X; Zhao SS; Dubash S; Dean LE; Jones GT; Marzo-Ortega H
    Rheumatology (Oxford); 2021 Dec; 60(12):5795-5800. PubMed ID: 33502476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis.
    Ortolan A; Webers C; Sepriano A; Falzon L; Baraliakos X; Landewé RB; Ramiro S; van der Heijde D; Nikiphorou E
    Ann Rheum Dis; 2023 Jan; 82(1):142-152. PubMed ID: 36261247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety Profile of Upadacitinib up to 5 Years in Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis: An Integrated Analysis of Clinical Trials.
    Burmester GR; Stigler J; Rubbert-Roth A; Tanaka Y; Azevedo VF; Coombs D; Lagunes I; Lippe R; Wung P; Gensler LS
    Rheumatol Ther; 2024 Jun; 11(3):737-753. PubMed ID: 38683479
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of comorbidities and treatment between ankylosing spondylitis and non-radiographic axial spondyloarthritis in the United States.
    Zhao SS; Ermann J; Xu C; Lyu H; Tedeschi SK; Liao KP; Yoshida K; Moots RJ; Goodson NJ; Solomon DH
    Rheumatology (Oxford); 2019 Nov; 58(11):2025-2030. PubMed ID: 31081033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis.
    de Winter JJ; van Mens LJ; van der Heijde D; Landewé R; Baeten DL
    Arthritis Res Ther; 2016 Sep; 18(1):196. PubMed ID: 27586785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.